专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

81. 发明申请

WO2020117974A1 COMPOUNDS AND COMPOSITIONS FOR EYE TREATMENTS 审中-公开
公开(公告)号：WO2020117974A1
公开(公告)日：2020-06-11
申请号：PCT/US2019/064534
申请日：2019-12-04
申请人： AVEDRO, INC. , HILL, Jason , ADLER, Desmond , FRIEDMAN, Marc D. , KAMAEV, Pavel , SHERR, Evan
发明人： HILL, Jason , ADLER, Desmond , FRIEDMAN, Marc D. , KAMAEV, Pavel , SHERR, Evan
IPC分类号： A61K31/498 , C07D241/44 , C07D401/12 , C07D403/04 , C07D413/04 , C07D417/04 , A61P27/02
摘要： This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and/or hydrate and/or prodrug of the compound) that that generates cross-linking in the cornea in response to exposure to an electromagnetic irradiation. This disclosure also features compositions containing the same as well as other methods of using and making the same. The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a disease, disorder, or condition in which in which abnormal shaping of the cornea (e.g., thinning of the cornea, e.g., bilateral thinning of the cornea, e.g., bilateral thinning of the central, paracentral, or peripheral cornea; or steepening (e.g., bulging) of the cornea) contributes to the pathology and/or symptoms and/or progression of the disease, disorder, or condition. Non-limiting examples of such diseases, disorders, or conditions include: (i) corneal ectatic disorders; (ii) vision conditions; and (iii) diseases, disorders, or conditions that are sequela or comorbid with any of the foregoing or any disclosed herein. More particular non-limiting examples of such diseases, disorders, or conditions include keratoconus, keratoglobus, pellucid marginal degeneration, corneal ectasia (e.g., post-operative ectasia, e.g., post-LASIK ectasia), Terrien's marginal degeneration, myopia, hyperopia, astigmatism, irregular astigmatism, and presbyopia.

82. 发明申请

WO2019173762A1 MICRO-DEVICES FOR TREATMENT OF AN EYE 审中-公开
公开(公告)号：WO2019173762A1
公开(公告)日：2019-09-12
申请号：PCT/US2019/021436
申请日：2019-03-08
申请人： AVEDRO, INC.
发明人： ADLER, Desmond, Christopher , ZADNO, Reza , BAVIER, Paul , IANNETTA, David, C. , ZHANG, Jun
IPC分类号： A61F9/007
摘要： A micro-device for corneal cross-linking treatment includes a body including an outer portion and an inner portion. The outer portion is disposed about a periphery of the inner portion. The inner portion is shaped such that, when the body is positioned against a surface of an eye, the outer portion contacts the surface of the eye and the inner portion defines a chamber over a cornea of the eye. The micro-device includes an illumination system including a micro-optical element coupled to the body. The micro-optical element is configured to direct photoactivating light to the cornea of the eye when the body is positioned against the surface of the eye. The photoactivating light generates cross-linking activity with a cross-linking agent applied to the cornea.

83. 发明申请

WO2019173403A1 SYSTEM FOR EYE TRACKING DURING EYE TREATMENT 审中-公开
公开(公告)号：WO2019173403A1
公开(公告)日：2019-09-12
申请号：PCT/US2019/020839
申请日：2019-03-05
申请人： AVEDRO, INC.
发明人： ADLER, Desmond, Christopher , USHER, David , SMIRNOV, Kikhail, Z.
IPC分类号： A61F9/007 , A61F9/008
摘要： A corneal cross-linking system includes a light source configured to emit a photoactivating light. The system includes a spatial light modulator configured to receive the photoactivating light from the light source and provide a pixelated illumination. The spatial light modulator defines a maximum area for the pixelated illumination. The system includes a controller configured to cause the spatial light modulator to project a first pixelated illumination onto the cornea to photoactivate a cross-linking agent applied to a treatment area. The first pixelated illumination has an area that is smaller than the maximum area defined by the spatial light modulator. The controller is configured to determine movement of the cornea. In response to the movement, the controller controls the spatial light modulator to project a second pixelated illumination to the treatment area based on a translation and/or transformation of the first pixelated illumination to continue photoactivating the cross-linking agent.

84. 发明申请

WO2018156593A1 FORMULATIONS FOR EYE TREATMENTS 审中-公开
公开(公告)号：WO2018156593A1
公开(公告)日：2018-08-30
申请号：PCT/US2018/018970
申请日：2018-02-21
申请人： AVEDRO, INC.
发明人： FRIEDMAN, Marc, D. , KAMAEV, Pavel , COFFEY, Martin, Joseph , RAJPAL, Rajesh, K. , NICKLIN, Alexandra
IPC分类号： A61K31/525 , A61K31/14 , A61K31/198 , A61K31/245 , A61K31/045 , A61K31/726 , A61K47/34 , A61K9/08 , A61P27/02
摘要： Formulations, are used for eye treatments, e.g., cross-linking treatments. For example, a therapeutic formulation includes a photosensitizer and delivery agent(s), wherein the delivery agent(s) include at least one of: anesthetic agent(s), analgesic agent(s), tonicity agent(s), or shear-thinning, or viscosity-increasing agent(s). In another example, a method includes applying preparatory formulation(s) to increase a permeability of a corneal epithelium, and applying therapeutic formulation(s) to the epithelium, where the preparatory formulation(s) include zinc metalloproteinase, copper metalloproteinase, papain, bromelain, actinidin, ficain, N-acetylcysteine, ambroxol, carbocisteine, and/or erdosteine. In yet another example, a method includes applying therapeutic formulation(s) to a corneal epithelium to deliver the therapeutic formulation(s) to a stroma, and applying enhancement formulation(s) to the epithelium in response to applying the therapeutic formulation(s), where: the enhancement formulation(s) remove the therapeutic formulation(s) from the epithelium; close tight junctions of the epithelium; promote oxidation for the therapeutic agent(s); and/or further deliver the therapeutic formulation(s) to the stroma.

85. 发明申请

WO2017074500A1 SYSTEMS AND METHODS FOR CROSS-LINKING TREATMENTS OF AN EYE 审中-公开
标题翻译：用于眼睛交叉治疗的系统和方法
公开(公告)号：WO2017074500A1
公开(公告)日：2017-05-04
申请号：PCT/US2016/029559
申请日：2016-04-27
申请人： AVEDRO, INC.
发明人： FRIEDMAN, Marc, D. , KAMAEV, Pavel , SMIRNOV, Mikhail
IPC分类号： A61F9/007 , A61N5/06
CPC分类号： A61F9/0079 , A61F9/007 , A61F9/008 , A61F9/00825 , A61F2009/00851 , A61F2009/00872 , A61F2009/00893
摘要： A corneal treatment system includes an illumination system configured to deliver photoactivating light to a cross-linking agent applied to a cornea. The system includes a controller that receives input relating to a desired biomechanical change in the cornea and executes program instructions to: (i) determine, from a photochemical kinetic model, a three- dimensional distribution of cross-links for the cornea to achieve the desired biomechanical change in the cornea, where the photochemical kinetic model calculates the distribution of cross-links based on cross-linking from (A) reactions involving reactive oxygen species (ROS) including at least peroxides, superoxides, and hydroxyl radicals, and (B) reactions not involving oxygen; and (ii) determine at least one set of treatment parameters to achieve the distribution of cross-links. The at least one set of treatment parameters includes illumination parameters for the delivery of the photoactivating light. The illumination system delivers the photoactivating light according to the illumination parameters.
摘要翻译：角膜治疗系统包括照明系统，该照明系统被构造成将光活化光传递至施加于角膜的交联剂。该系统包括控制器，该控制器接收与角膜中期望的生物力学变化有关的输入并且执行程序指令以：（i）从光化学动力学模型确定角膜的交联的三维分布以实现期望的（A）涉及至少包括过氧化物，超氧化物和羟基自由基的活性氧（ROS）的反应和（B）自由基的交联，计算交联的分布，其中光化学动力学模型计算角膜中的生物力学变化，不涉及氧气的反应; 和（ii）确定至少一组治疗参数以实现交联的分布。该至少一组治疗参数包括用于递送光激活光的照射参数。照明系统根据照明参数提供光活化光。

86. 发明申请

WO2017015471A1 SYSTEMS AND METHODS FOR TREAMENTS OF AN EYE WITH A PHOTOSENSITIZER 审中-公开
标题翻译：眼睛与光敏剂物质的系统和方法
公开(公告)号：WO2017015471A1
公开(公告)日：2017-01-26
申请号：PCT/US2016/043359
申请日：2016-07-21
申请人： AVEDRO, INC.
发明人： KAMAEV, Pavel , FRIEDMAN, Marc
IPC分类号： A61K31/525 , A61K47/34 , A61P27/02 , A61P31/04 , A61P33/02 , A61N5/06
CPC分类号： A61K41/0057 , A61F9/0017 , A61F9/0079 , A61K9/0048 , A61K31/525 , A61K33/00 , A61K47/02 , A61N5/062 , A61N2005/0661
摘要： A formulation for an eye treatment includes a photosensitizer and a permeability enhancing composition. The permeability enhancing composition includes one or more permeability enhancers. The permeability enhancing composition has a hydrophilic and lipophilic balance increases a permeability of an area of the eye for the photosensitizer. The hydrophilic and lipophilic balance can be characterized by a Hydrophile-Lipophile Balance (HLB) number. For example, the area of the eye may include a corneal epithelium, the photosensitizer may include riboflavin, and the permeability enhancing composition may have a corresponding HLB number between approximately 12.6 and approximately 14.6.
摘要翻译：用于眼部治疗的制剂包括光敏剂和渗透性增强组合物。渗透性提高组合物包括一种或多种渗透性增强剂。渗透性提高组合物具有亲水和亲油平衡，增加了光敏剂的眼睛面积的渗透性。亲水和亲油平衡可以通过亲水亲油平衡（HLB）数来表征。例如，眼睛的面积可以包括角膜上皮，光敏剂可以包括核黄素，并且渗透性增强组合物可以具有约12.6至约14.6之间的相应HLB数。

87. 发明申请

WO2016077747A1 MULTIPASS VIRTUALLY IMAGED PHASED ARRAY ETALON 审中-公开
标题翻译：多个虚拟的虚拟幻灯片ETALON
公开(公告)号：WO2016077747A1
公开(公告)日：2016-05-19
申请号：PCT/US2015/060667
申请日：2015-11-13
申请人： AVEDRO, INC.
发明人： BUKSHTAB, Michael, A. , FRIEDMAN, Marc
IPC分类号： A61B3/10 , G01J3/22
CPC分类号： G02B21/0056 , A61B3/13 , A61B3/14 , A61B5/0068 , A61B5/0075 , G01B9/02044 , G01J3/00 , G02B17/006 , G02B21/0048
摘要： An example system determines biomechanical properties of eye tissue. The system includes a confocal microscopy system configured to scan the incident light across a plurality of cross-sections of the tissue. The incident light is reflected by the plurality of cross-sections of tissue as scattered light. The system includes a spectrometer to receive the scattered light and provide spectral information for the scattered light. The system includes processor(s) to determine a Brillouin frequency shift from the spectral information and to generate a three-dimensional profile of the corneal tissue according to the Brillouin frequency shift. The three-dimensional profile provides an indicator of one or more biomechanical properties of the tissue. The spectrometer includes a multipass optical device that generates an interference pattern from the scattered light. The interference pattern provides the spectral information for the scattered light. The spectrometer includes a camera to detect the interference pattern from the optical device.
摘要翻译：示例系统确定眼组织的生物力学性质。该系统包括配置成扫描穿过组织的多个横截面的入射光的共焦显微镜系统。入射光被组织的多个横截面反射为散射光。该系统包括用于接收散射光并提供散射光的光谱信息的光谱仪。该系统包括从光谱信息确定布里渊频移并且根据布里渊频移产生角膜组织的三维轮廓的处理器。三维轮廓提供组织的一个或多个生物力学性质的指示。光谱仪包括从散射光产生干涉图案的多光学光学装置。干涉图案为散射光提供光谱信息。光谱仪包括用于检测来自光学装置的干涉图案的照相机。

88. 发明申请

WO2013052511A3 SYSTEMS AND METHODS FOR APPLYING AND MONITORING EYE THERAPY 审中-公开
标题翻译：用于应用和监测眼睛治疗的系统和方法
公开(公告)号：WO2013052511A3
公开(公告)日：2013-07-04
申请号：PCT/US2012058500
申请日：2012-10-02
申请人： AVEDRO INC
发明人： FRIEDMAN MARC D , MULLER DAVID , SHERR EVAN A
IPC分类号： A61F9/00 , A61B3/107
CPC分类号： A61F9/0079 , A61B3/1015 , A61B3/102 , A61B3/135 , A61B3/16 , A61B8/10 , A61F9/008 , A61F2009/00844 , A61F2009/00872
摘要： In systems and methods for generating cross-linking activity in an eye, a feedback system monitors a biomechanical strength of the eye in response to the photoactivation of a cross-linking agent applied to an eye. The feedback system includes a perturbation system that applies a force to the eye and a characterization system that determines an effect of the force on the eye. The effect of the force provides an indicator of the biomechanical strength of the eye. The characterization system determines the effect of the force on the eye by measuring an amount of deformation caused by the force or a rate of recovery from the deformation.
摘要翻译：在用于在眼睛中产生交联活性的系统和方法中，响应于施加到眼睛的交联剂的光活化，反馈系统监测眼睛的生物力学强度。反馈系统包括对眼睛施加力的扰动系统和确定力对眼睛的影响的表征系统。力的作用提供了眼睛生物力学强度的指标。表征系统通过测量由力引起的变形量或从变形恢复的速率来确定力对眼睛的影响。

89. 发明申请

WO2012145159A1 CONTROLLED CROSS-LINKING INITIATION AND CORNEAL TOPOGRAPHY FEEDBACK SYSTEMS FOR DIRECTING CROSS-LINKING 审中-公开
标题翻译：控制交叉引导和导向交叉连接的角度反射系统
公开(公告)号：WO2012145159A1
公开(公告)日：2012-10-26
申请号：PCT/US2012/032024
申请日：2012-04-03
申请人： AVEDRO, INC. , MULLER, David , MARSHALL, John , FRIEDMAN, Marc , BLINN, Stephen , SCHARF, Stephen , KAMAEV, Pavel , PERTAUB, Radha
发明人： MULLER, David , MARSHALL, John , FRIEDMAN, Marc , BLINN, Stephen , SCHARF, Stephen , KAMAEV, Pavel , PERTAUB, Radha
IPC分类号： A61F9/01 , A61F9/008
CPC分类号： A61N5/062 , A61B2018/00619 , A61F9/0079 , A61F2009/00844 , A61F2009/00872 , A61F2009/00882
摘要： Devices and approaches for activating cross-linking within corneal tissue to stabilize and strengthen the corneal tissue following an eye therapy treatment. A feedback system is provided to acquire measurements and pass feedback information to a controller. The feedback system may include an interferometer system, a corneal polarimetry system, or other configurations for monitoring cross-linking activity within the cornea. The controller is adapted to analyze the feedback information and adjust treatment to the eye based on the information. Aspects of the feedback system may also be used to monitor and diagnose features of the eye. Methods of activating cross-linking according to information provided by a feedback system in order to improve accuracy and safety of a cross-linking therapy are also provided.
摘要翻译：用于激活角膜组织内的交联以在眼睛治疗治疗之后稳定和加强角膜组织的装置和方法。提供反馈系统以获取测量并将反馈信息传递给控制器。反馈系统可以包括干涉仪系统，角膜偏振仪系统或用于监测角膜内的交联活动的其它构型。该控制器适用于分析反馈信息，并根据信息调整眼睛治疗。反馈系统的方面也可用于监测和诊断眼睛的特征。还提供了根据反馈系统提供的信息激活交联的方法，以提高交联疗法的准确性和安全性。

90. 发明申请

WO2011053768A3 SYSTEM AND METHOD FOR STABILIZING CORNEAL TISSUE AFTER TREATMENT 审中-公开
标题翻译：治疗后稳定角膜组织的系统和方法
公开(公告)号：WO2011053768A3
公开(公告)日：2011-11-24
申请号：PCT/US2010054673
申请日：2010-10-29
申请人： AVEDRO INC , MULLER DAVID , MARSHALL JOHN
发明人： MULLER DAVID , MARSHALL JOHN
IPC分类号： A61N5/02 , A61F7/00 , A61F9/007 , A61K38/18 , A61K38/20 , A61M35/00 , A61P27/02
CPC分类号： A61F9/007 , A61B18/1815 , A61B2018/00029 , A61F9/0079 , A61F9/013 , A61F2009/00872 , A61K38/1841 , A61M35/00 , A61M2210/0612
摘要： Embodiments according to aspects of the present invention provide systems and methods for stabilizing corneal tissue after treatment of the corneal tissue. For example, thermokeratoplasty may be applied to the corneal tissue to address disorders associated with abnormal shaping of the cornea. To stabilize the desired structural changes caused by the treatment, embodiments apply ophthalmic formulations that help to inhibit wound healing. Wound healing may occur in response to the application of the treatment and may produce further structural changes that mitigate or alter the desired effects of the treatment.
摘要翻译：根据本发明的方面的实施例提供了用于在角膜组织处理之后稳定角膜组织的系统和方法。例如，热角膜成形术可以应用于角膜组织以解决与角膜异常成形相关的疾病。为了稳定由治疗引起的期望的结构变化，实施方案应用有助于抑制伤口愈合的眼用制剂。伤口愈合可能会因应用治疗而发生，并可能产生进一步的结构变化，从而减轻或改变预期的治疗效果。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式